Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44011   clinical trials with a EudraCT protocol, of which   7317   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2008-006953-41
    Sponsor's Protocol Code Number:C08-002B
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2009-02-26
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2008-006953-41
    A.3Full title of the trial
    AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)
    A.4.1Sponsor's protocol code numberC08-002B
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorALEXION PHARMACEUTICALS, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name SOLIRIS
    D.2.1.1.2Name of the Marketing Authorisation holderALEXION EUROPE
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNeculizumab
    D.3.9.2Current sponsor codeh5G1.1-mAb
    D.3.9.3Other descriptive nameAnti-C5 antibody
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Adolescent patients (from 12 and up to 18 years of age) with plasma therapyresistant Atypical Hemolytic-Uremic Syndrome (aHUS).
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10018932
    E.1.2Term Haemolytic uraemic syndrome
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) as
    indicated by thrombocytopenia as measured by platelet count change from baseline through the treatment period in patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).
    E.2.2Secondary objectives of the trial
    • Evaluate additional efficacy endpoints such as the effect of eculizumab on:
    − TMA Intervention Rate (# PT and # Dialysis Events/Patient/Day) during the
    Treatment Period compared with the TMA Intervention Rate prior to the first
    dose of Investigational Product.
    − TMA-Event Free status defined as the absence of [1] decrease in platelet
    count of >25% from the Platelet Count Pre-PT Baseline Set-Point; [2] PT
    while the patient is receiving eculizumab, and [3] new dialysis for at least12
    weeks.
    − Key Hemolytic measures.
    − Quality of Life measures.
    − Renal function measures.
    − TMA Remission.
    • Characterize the overall safety and tolerability of eculizumab.
    • Describe the pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab
    in patients with aHUS.
    • Perform a series of exploratory efficacy analyses.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female patients from 12 and up to 18 years of age who have been diagnosed with Atypical Hemolytic-Uremic Syndrome (aHUS). Patients may be newly
    diagnosed, experiencing a relapse of the disease, or having a post-transplant
    recurrence of the disease.
    2. Patients must exhibit a decrease in platelet count despite at least 4 Plasma Therapy (PT) treatments in the 1 week immediately prior to screening. At screening, platelet count must be < 150 x 10^9/L and at least 25% lower than the average of 3 platelet counts obtained during remission and at least 1 month apart over the 12 months prior to screening (designated the “average remission platelet count”).
    3. If historical counts are not available, platelet count at screening must be < 75 x 10^9/L despite PT treatment administration of at least 4 PT treatments in the 1 week
    immediately prior to screening.
    4. Known complement regulatory protein genetic abnormality, i.e., a mutation in
    Complement Protein 3, factor H or associated factor, factor I, or membrane cofactor
    protein 1 (MCP-1) or known Factor B gain-of-function mutation, or known Anti-
    CFH antibody (“aHUS lesions”).
    • Patients diagnosed with aHUS with any of these aHUS lesions are eligible and
    will be assigned to one of the following parallel categories during the treatment
    period of the trial:
    − (Category 1) Complement Protein 3 or factor H or factor I functional
    deficiency or abnormal factor interaction (C3/CFH/CFI FFP Group);
    − (Category 2) Factor B Gain of Function;
    − (Category 3) Anti-CFH Antibody (anti-CFH Group);
    − (Category 4) MCP-1 deficiency (MCP-1 Group);
    5. Patients diagnosed with HUS of the atypical type without documented complement
    regulatory protein genetic abnormality or known anti-CFH antibody are eligible if
    other etiologies of HUS have been ruled out as confirmed in the Exclusion Criteria
    (i.e., including Shiga-toxin negative, non-infectious, non-drug-exposure-related [e.g.,
    cyclosporine]), no known HIV positivity, and anti-phospholipid antibody negative).
    Thrombotic thrombocytopenic purpura also must be ruled out (i.e., ADAMTS-13
    activity must be > 5%; see Exclusion Criteria). Patients meeting these conditions
    will be assigned to Category 5. In addition, these patients will undergo genetic
    testing to determine if a mutation can be identified. If a mutation is identified, the
    patient will be reassigned to the appropriate category.
    6. Lactate dehydrogenase (LDH) level ≥ ULN;
    7. Creatinine level ≥ ULN for age (patients requiring acute dialysis for acute renal
    failure also eligible).
    8. Female patients of childbearing potential must be practicing an effective, reliable and medically acceptable contraceptive regimen during the entire duration of the study, including the follow-up period.
    9. Patient’s parents/legal guardian must be willing and able to give written informed
    consent and patients must be willing to give written informed assent (if applicable as
    determined by the IRB/IEC).
    10. Able and willing to comply with study procedures.
    E.4Principal exclusion criteria
    1. ADAMTS-13 inhibitor or deficiency (i.e., ADAMTS-13 activity <5%) as measured
    at the screening visit.
    2. Malignancy.
    3. Typical HUS (Shiga toxin +).
    4. Known HIV infection.
    5. Identified drug exposure-related HUS.
    6. Infection-related HUS.
    7. Renal function status requiring chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy).
    8. Patients with a confirmed diagnosis of sepsis defined as positive blood cultures
    within 7 days of the screening visit and not treated with antibiotics to which the
    organism is sensitive.
    9. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease.
    10. Pregnancy or lactation.
    11. Unresolved meningococcal disease.
    12. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody
    positivity or syndrome.
    13. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient’s risk by participating in the study or confound the outcome of the study.
    14. Patients receiving IVIg or Rituximab therapy.
    15. Patients receiving other immunosuppressive therapies such as steroids, mTOR
    inhibitors or FK506 inhibitors are excluded unless: [1] part of a post-transplant antirejection regime, [2] patient has confirmed anti-CFH antibody requiring
    immunosuppressive therapy and [3] dose of such medications have been unchanged
    for at least 4 weeks prior to the screening period.
    16. Patients receiving Erythrocyte stimulating agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period.
    17. Participation in any other investigational drug trial or exposure to other
    investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial.
    E.5 End points
    E.5.1Primary end point(s)
    Platelet count change from baseline (Platelet Count Pre-PT Baseline Set-point
    value) after first dose of Investigational Product.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    The protocol has pre-defined objectives and pre-specified end points to assess eculizumab’s efficacy
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    In protocol each patient serves as his/her own control as described by the endpoints in the protocol
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA25
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Yes
    F.3.3.7.1Details of other specific vulnerable populations
    Non Adult Subjects
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 4
    F.4.2.2In the whole clinical trial 7
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients may be eligible to enroll in an open-label extension study after completing study evaluations to Week 26.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2009-03-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2009-08-05
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA